Purpose. To examine the role of preoperative magnetic resonance imaging (pMRI) on time to surgery and rates of reoperation and contralateral prophylactic mastectomy (CPM) using a population-based study of New Jersey breast cancer patients. Methods. The study included 289 African-American and 320 white women who participated in the Breast Cancer Treatment Disparity Study and underwent breast surgery for newly diagnosed early-stage breast cancer between 2005 and 2010. Patients were identified through rapid case ascertainment by the New Jersey State Cancer Registry. Association between pMRI and time to surgery was examined by using linear regression and, with reoperation and CPM, by using binomial regression. Results. Half (49.9 %) of the study population received pMRI, with higher use for whites compared with AfricanAmericans (62.5 vs. 37.5 %). After adjusting for potential confounders, patients with pMRI versus those without experienced significantly longer time to initial surgery [geometric mean = 38.7 days; 95 % confidence interval (CI) 34.8-43.0; vs. 26.5 days; 95 % CI 24.3-29.0], a significantly higher rate of CPM [relative risk (RR) = 1.82; 95 % CI 1.06-3.12], and a nonsignificantly lower rate of reoperation (RR = 0.76; 95 % CI 0.54-1.08). Conclusions. Preoperative MRI was associated with significantly increased time to surgery and a higher rate of CPM, but it did not affect the rate of reoperation.
Current guidelines recommend bilateral mammography as the primary modality and, if necessary, ultrasonography to determine tumor extent preoperatively and plan surgical treatment of early-stage breast cancer (BC). 1 There are no recommendations supporting the routine use of preoperative magnetic resonance imaging (pMRI) in surgical planning of BC because of a lack of data showing a survival advantage associated with its use. In addition, the few studies that examined the impact of pMRI on BC recurrence have failed to show any benefits. [2] [3] [4] Despite the lack of proven benefits on patient outcomes, use of pMRI has increased significantly in the past decade. [5] [6] [7] [8] The growing popularity of pMRI has been based on the assumption that its increased detection capability will result in wider excision and removal of additional disease and, therefore, will improve immediate surgical outcomes. 9 Research evaluating pMRI mostly includes single-institution studies on reoperation, and most have found no improvement related to pMRI. 3, 4, [10] [11] [12] [13] [14] [15] [16] There are also concerns that pMRI may be associated with recent increases in contralateral prophylactic mastectomy (CPM) and that procedures required to evaluate the findings of pMRI may result in unnecessary increases in time to surgery. 5, 7, 8, 17, 18 The limited number of studies that have examined the role of pMRI on CPM rates and time to surgery either reported conflicting findings or were unable to adjust for important confounders. 7, 8, [18] [19] [20] [21] The available evidence is therefore insufficient to determine whether pMRI should be included in the routine work-up of BC patients. We conducted a population-based study to investigate the role of pMRI on time to surgery as well rates of reoperation and CPM among early-stage BC patients.
METHODS

Study Population and Data Collection
The study population was selected from patients included in the Breast Cancer Treatment Disparity Study (BCTDS). The BCTDS is composed of African-American (AA) and white women who participated in the Women's Circle of Health Study (WCHS), diagnosed with stage I, II, and T3N1M0 BC between 2005 and 2010, with no history of cancer other than nonmelanoma skin cancer, and age B85 years. The WCHS is a multisite case-control study in New York City and New Jersey designed to evaluate risk factors for early and aggressive BC in AA and white women. 22, 23 The BCTDS cohort included New Jersey cases from the WCHS who were identified from all major hospitals in seven counties, including Bergen, Essex, Hudson, Mercer, Middlesex, Passaic, and Union, through rapid case ascertainment by the New Jersey State Cancer Registry staff. A total of 634 patients comprised the BCTDS population. Written informed consents were obtained from all patients who agreed to participate, and the study was approved by institutional review board at all participating institutions.
All BCTDS patients were included in the current study, except for those who did not undergo breast excision after diagnosis (n = 25), resulting in a total of 609 patients. Patients included in the study consented to release of their medical records and provided contact information of health care providers involved in their BC care. These providers were contacted to obtain medical records for abstracting information on sociodemographics, family history, cancer suspicion, preoperative and diagnostic investigations, tumor pathology results, and surgical and adjuvant treatment(s). Data were also collected on date of cancer suspicion as well as dates of administration for various tests, procedures, and adjuvant treatments. Abstractors were blinded to study hypothesis, and they participated in a standardized training to ensure uniformity of information ascertainment, check for completeness, and prevent systematic differences in data collection between abstractors.
Preoperative MRI
In all cases, BC was pathologically confirmed either by percutaneous or surgical biopsy. Consequently, first breast excision performed after pathologic diagnosis was defined as initial surgery and consisted of either breast-conserving surgery (BCS) or mastectomy. A patient who received an MRI any time between the date of cancer suspicion and the date of initial surgery was classified as a pMRI recipient. Patients who did not receive an MRI in this time period were categorized into the no-pMRI group.
Outcomes
Time to surgery was calculated as the interval in days from pathologic diagnosis to initial surgery. Subjects who received neoadjuvant chemotherapy were further excluded from analysis of time to surgery (n = 33). Reoperation was defined as at least one repeat operation performed after the initial surgery. It consisted of either reexcision after initial BCS or initial mastectomy, or mastectomy after initial BCS. CPM was defined as removal of the unaffected breast along with the affected breast.
Additional Variables
We examined sociodemographics and clinical characteristics, including age at diagnosis, race, education, health insurance, body mass index (BMI), family history of BC (first degree, second degree, or none), method of cancer detection (by patient, physician, or screening mammography), receipt of additional investigations (diagnostic mammogram and ultrasonography, additional biopsy after diagnosis, and genotype testing done for mutations in BRCA1 and BRCA2 genes), and method of diagnosis (percutaneous or surgical biopsy). Tumor characteristics examined were grade; histology; size; lymph node status; presence of multifocality or multicentricity; and estrogen, progesterone, and human epidermal growth factor 2 receptor statuses. Margin status at initial surgery was classified into positive, close (B1 mm), and negative. Treatment information, including type of initial surgery, surgical facility (teaching or community), and receipt of adjuvant chemotherapy and hormonal therapy, was also obtained.
Statistical Analysis
Sociodemographic and clinical characteristics, tumor pathology, and treatment status of the study population were tabulated by receipt of pMRI. Time to surgery and rates of reoperation and CPM were compared between the two pMRI groups as well by various subject characteristics. Time to surgery (days) was log transformed because of its positively skewed distribution, and regression diagnostics were used to check for influential observations. Four outliers were identified that were further excluded from analysis of time to surgery (final n = 572). Linear regression through general linear model was used to estimate unadjusted and adjusted geometric mean with 95 % confidence interval (CI) for time to surgery. Geometric means were obtained by exponentiation of parameter estimates from linear regression. Reoperation and CPM rates were examined for all 609 patients in the study. They were reported as percentages, and the chi-square test was used to compare rates. Univariate and multivariate binomial regression models were used to examine the association between pMRI and reoperation and CPM. The binomial associations were expressed as relative risk (RR) and 95 % CI by using nonlinear programming. The variables included in the multivariate models were selected according to prior knowledge, as well the association of the variable with both pMRI and study outcomes, while keeping a parsimonious approach in mind. The adjusted model for time to surgery included age, race, education, insurance, and type of initial surgery. The multivariate model for reoperation was adjusted for age, race, education, insurance, BMI, method of diagnosis, histology, multifocality or multicentricity, and surgical facility. The multivariate model for CPM was adjusted for age, race, education, insurance, BMI, family history, genotype testing, clinical presentation, multifocality or multicentricity, and surgical facility. Associations with p values less than 0.05 were considered statistically significant. We also explored findings from additional biopsies that patients received after their pathologic diagnosis by receipt of pMRI. All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Of the total 609 BC patients included in the study, 49.9 % (304 of 609) received pMRI. As shown in Table 1 , patients receiving pMRI compared with those without were more likely to be younger, white, with higher education, covered by private health insurance, and of normal weight. They were also more likely to have a family history of BC, self-discover their BC, undergo diagnostic ultrasound and genotype testing, receive additional biopsies, and get diagnosed by percutaneous biopsy. According to tumor and treatment characteristics (Table 2) , patients who received pMRI more commonly had positive lymph nodes and multifocal or multicentric cancer. However, no differences CPM was observed for patients with pMRI than for those without (16.1 and 5.2 %, respectively; p \ 0.001). Distribution of study outcomes by different patient characteristics is presented in Table 4 . Time to initial surgery was significantly longer for AA and for mastectomy patients. Higher reoperation rates were seen for higher BMI, diagnosis by percutaneous biopsy, positive or close margins on initial surgery, and receipt of surgery in a community hospital. Conversely, rates of CPM were higher among those with a younger age, white race, private health insurance, lower BMI, family history of BC, self-recognized cancer, receipt of a genotype test, and presence of multifocal or multicentric tumor. Table 5 presents unadjusted and adjusted association between pMRI and study outcomes. Results from adjusted linear regression showed that patients who received pMRI experienced a significantly longer time from diagnosis to initial surgery (geometric mean = 38.7 days; 95 % CI 34.8-43.0) as compared with patients who did not (geometric mean = 26.5 days; 95 % CI 24.3-29.0). Receipt of pMRI was not associated with significant reduction in reoperation rate, both in the unadjusted (RR = 0.89; 95 % CI 0.64-1.23) and adjusted (RR = 0.76; 95 % CI 0.54-1.08) models. In the unadjusted model, the risk of undergoing CPM was more than three times higher for patients who received pMRI compared with those who did not (RR = 3.07; 95 % CI 1.79-5.28). After adjustment for potential confounders including age, race, education, insurance, BMI, family history, genotype testing, clinical presentation, multifocality or multicentricity, and surgical facility, receipt of pMRI was associated with an RR of 1.82 (95 % CI 1.06-3.12) of undergoing CPM.
The exploratory analysis showed that 10.2 % (31 of 304) and 4.6 % (14 of 305) patients with and without pMRI, respectively, received additional biopsy after the pathologic diagnosis. These additional biopsies resulted in positive findings (including additional foci of invasive or in situ carcinoma) among 16 of 31 (51.6 %) patients with pMRI and 8 of 14 (57.1 %) patients without pMRI (p [ 0.05).
DISCUSSION
Use of pMRI has gained worldwide popularity in surgical planning of BC because of its proven superior accuracy in detecting additional disease compared with conventional imaging. Because of the steep rise in pMRI use in the absence of improved patient outcomes, it becomes clinically meaningful to understand its impact on short-term surgical outcomes. In this study we examined the association of pMRI with time to surgery, reoperation, and CPM among early-stage BC patients. Approximately half of the study population received pMRI, and 18.8 and 10.7 % underwent reoperation and CPM, respectively. Patients receiving pMRI experienced a significantly longer time to initial surgery and 1.82 times the risk of undergoing CPM, but no difference in reoperation rate, as compared with those who did not receive pMRI.
Only two US-based studies to date have examined the impact of pMRI on time to surgical treatment. Bleicher et al. reported mean times of 57 and 38 days (p = 0.01), and Hulvat et al. reported median times of 43 and 32 days (p = 0.054) in pMRI and no-pMRI groups, respectively. 18, 21 However, these studies reported unadjusted results, which can lead to biased estimates due to a large impact of patient characteristics such as socioeconomic status, access to care, and race, as well as tumor characteristics, on treatment delay. This was true for our study population as well, because a longer time to surgery was observed for AAs and for those undergoing mastectomy. After adjusting for differences related to age, race, education, insurance, and type of initial surgery, we found that pMRI subjects experienced a significantly longer time to initial surgery (38.9 vs. 27.5 days). The longer delay seen for pMRI group can be explained by additional tests and biopsies that are conducted to investigate MRI findings. The difference seen between the two groups may not have a detrimental effect on treatment outcome, but a longer time taken to initiate surgery may result in increased patient anxiety and treatment dissatisfaction. 21 In large part, single-institution studies have examined differences in reexcision rates by receipt of pMRI. The majority of these reports showed no differences, except for one by Mann et al., in which a significantly lower rate of reexcision, at 5 %, was seen for patients who received pMRI, in comparison to 15 % for those who did not. 3, [10] [11] [12] [13] 15, 16 Two recent European randomized trials evaluated the efficacy of pMRI among BC patients. One of them reported no association between pMRI and reexcision within 6 months of randomization (odds ratio = 0.96; 95 % CI 0.75-1.24). 4 The second trial, conversely, found a significant increase in reexcision after BCS in the pMRI group (34 %) versus the control group (12 %). 14 The rate of reoperation seen in our study is similar to these preexisting reports and concurs with most of the available evidence that there is no benefit associated with pMRI on reoperation.
There has been a significant increasing trend in CPM rates nationwide even though it provides minimal or no survival benefits. [24] [25] [26] [27] CPM is particularly recommended for patients who are at high risk of developing bilateral BC; however, most women who choose to undergo CPM are not at high risk. 7, 19, [28] [29] [30] [31] [32] [33] [34] A combination of both patient and clinical factors has been associated with its increased use. Few studies have examined pMRI as a predictor of CPM and reported different conclusions. 7, 8, 19, 20 Sorbero et al. and King et al. showed a significantly increased risk of CPM associated with pMRI, whereas two studies did not find any association. 7, 8, 19, 20 Additionally, many of them were limited in their ability to control for important confounders. For example, almost all of them did not have information on socioeconomic variables such as education and insurance, and some were unable to adjust important clinical variables as well. Results from our analysis also show that pMRI was associated with a high risk of CPM, although the RR declined considerably after adjustment for several relevant sociodemographic and clinical predictors (unadjusted RR = 3.07 vs. adjusted RR = 1.82). In our study, patients receiving CPM compared with those who did not were selectively very different. CPM patients were more likely to be younger, white, of higher socioeconomic status, privately insured, and with a family history of BC and, therefore, comprised a group of more health-conscious patients. It is possible that these patients proactively ask for pMRI and/or that the treating oncologist prefers to do more extensive work-ups on these patients. As a result, after adjustment for these factors, the RR was minimized, but it was not eliminated completely, hence suggesting that pMRI is one of the independent predictors that may influence patients' decision to opt for CPM.
A longer delay or excess of surgeries observed for the pMRI group can be considered useful if, in fact, it increases the chances of identifying additional cancer as compared with the no-pMRI group. In our study, although the pMRI group was twice as likely to undergo additional biopsy, no difference was seen in proportions with positive findings on biopsies by receipt of pMRI.
Our study had some potential limitations. We were unable to evaluate whether the decision to undergo CPM was based on findings of pMRI. We also did not have data on other additional tests that may have been performed to investigate pMRI findings and their influence on surgical outcomes. The study, however, uses the strength of detailed clinical information available in medical records such that confounding by indication is not a major issue. Additionally, this is a population-based study including many hospitals in a diverse area, and this provides increased generalizability about the impact of pMRI on surgical outcomes, in contrast to most of the existing reports that are single-institution based.
In conclusion, we found that pMRI did not offer any substantial benefits in surgical management of BC patients. The reoperation rates did not differ significantly by receipt of pMRI. Additionally, pMRI had a significant influence on receipt of CPM and in increasing time to surgery. We recommend that patients should be counseled about the lack of benefits of pMRI during surgical decision making.
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